4.7 Article

The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment

期刊

ALZHEIMERS & DEMENTIA
卷 11, 期 12, 页码 1510-1519

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2015.05.014

关键词

White matter hyperintensities; CSF tau; Alzheimer's disease; Mild cognitive impairment

资金

  1. DoD [W81XWH-12-1-0013]
  2. NIH [R01 AG034189]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) [U01 AG024904]
  4. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc
  11. Biogen Idec Inc
  12. Bristol-Myers Squibb Company
  13. Eisai Inc
  14. Elan Pharmaceuticals, Inc
  15. Eli Lilly and Company
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd
  18. Genentech, Inc
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Medpace, Inc
  25. Merck Co, Inc
  26. Meso Scale Diagnostics, LLC
  27. NeuroRx Research
  28. Neurotrack Technologies
  29. Novartis Pharmaceuticals Corporation
  30. Pfizer Inc
  31. Piramal Imaging
  32. Servier
  33. Synarc Inc
  34. Takeda Pharmaceutical Company
  35. Canadian Institutes of Health Research

向作者/读者索取更多资源

Introduction: It is unclear whether white matter hyperintensities (WMHs), magnetic resonance imaging markers of small-vessel cerebrovascular disease, promote neurodegeneration and associated clinical decline in Alzheimer's disease (AD), or simply co-occur with recognized pathogenic processes. Methods: In 169 patients with mild cognitive impairment, followed for 3 years, we examined the association of (1) baseline regional WMH and cerebral spinal fluid-derived t-tau (total tau) with entorhinal cortex atrophy rates, as a marker of AD-related neurodegeneration, and conversion to AD; and (2) baseline regional WMH with change in t-tau level. Results: In participants with low baseline t-tau, higher regional WMH volumes were associated with faster entorhinal cortex atrophy. Higher parietal WMH volume predicted conversion to AD in those with high t-tau. Higher parietal and occipital WMH volumes predicted increasing t-tau. Discussion: WMHs affect AD clinical and pathologic processes both directly and interacting with tau. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据